Human immunodeficiency virus 1 antigens (HIV-1 antigens)

Human immunodeficiency virus 1 (HIV-1) antigens encompass the entire suite of proteins encoded by the HIV-1 genome, including structural proteins (Gag), enzymes (Pol), envelope glycoproteins (Env), and various regulatory and accessory proteins (Tat, Rev, Nef, Vif, Vpr, Vpu). These antigens are critical for the viral life cycle, facilitating processes such as host cell attachment, membrane fusion, reverse transcription of viral RNA into DNA, integration into the host genome, and the assembly of new virions. In the context of clinical medicine, these proteins serve as the primary targets for antiretroviral therapy (ART) and are the focus of vaccine development efforts. For example, the p24 capsid protein is a major diagnostic marker, while the gp120 and gp41 envelope proteins are targets for entry inhibitors and neutralizing antibodies. Because this term refers to a broad collection of distinct proteins rather than a single molecular entity, it is often considered a multi-target category in drug discovery. Effective management of HIV-1 infection typically requires a combination of drugs targeting multiple different antigens simultaneously to suppress viral replication and prevent the emergence of resistant strains.

Other names

HIV-1 proteinsHIV-1 viral proteinsHIV-1 gene productsHuman immunodeficiency virus type 1 antigens

Nucleoside reverse transcriptase inhibition (NRTI), Non-nucleoside reverse transcriptase inhibition (NNRTI), Protease inhibition (PI), Integrase strand transfer inhibition (INSTI), Capsid inhibition, Attachment inhibition, Fusion inhibition